Nan Fang, Founder and Chief Executive Officer, Singleron Biotechnologies, shared a post on LinkedIn:
“The most talked about news in biotech NOW: Moderna and Merck announced that their Phase 3 trial of a personalized mRNA cancer vaccine plus Keytruda hit its primary endpoint — significantly reducing melanoma recurrence versus Keytruda alone in patients with surgically-removed high-risk melanoma. This is a great breakthrough, first success story of a new drug modality that brings hope to cancer patients.
Single cell analysis technologies can play an important role in the development of such mRNA cancer vaccine, by giving high resolution information on both tumor cells and their micro-environment. As showing in this Cell Reports Medicine paper from our customers, where FocuSCOPE Single Cell mRNA X Liver Cancer Mutation kit was used to evaluate the targeted elimination of tumor cells harboring certain mutations by neoantigen mRNA vaccine.
In a clinical setting, such single cell method can be used in designing personalized mRNA vaccine: by analyzing tumor sample to gain information on which mutations are present in every tumor cell versus only a subset, effective mRNA vaccines can be designed to target all tumor cells.”
Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15+ CD8+ T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma
Authors: Xinyi Lin, Geng Chen, Ruijing Tang, Ming Wu, Da Zhang, Fangzhou Lin, Jianhua Guan, Jing Yang, Xiuqing Dong, Xiaoyuan Zheng, Liman Qiu, Haijun Yu, Zhixiong Cai, Xiaolong Liu.
Read the Full Article on Cell Reports Medicine
You can also read: Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma
